Filippo Cademartiri: 3 Biomarkers Are Better Than 1: Refining ASCVD Risk in MESA
Filippo Cademartiri, Consultant Advanced Cardiovascular Imaging at UPMC Salvator Mundi International Hospital, shared on LinkedIn:
”Three biomarkers are better than one: refining ASCVD risk in MESA
Traditional risk assessment often treats biomarkers in isolation.
This large analysis from the Multi-Ethnic Study of Atherosclerosis (MESA) shows why that approach may miss the people at highest cardiovascular risk.
What was studied?
Researchers evaluated the individual and combined effects of:
Lipoprotein(a) [Lp(a)]
High-sensitivity CRP (hs-CRP)
Total homocysteine (tHcy)
on coronary heart disease (CHD) and stroke over ~16 years of follow-up in >6,600 asymptomatic adults.
Key findings
Alone, biomarkers showed modest or inconsistent associations.
Risk rose sharply only when biomarkers were elevated together.
Individuals with all three elevated had:
~2× higher risk of CHD
~3× higher risk of stroke
In contrast, having just one elevated marker often did not meaningfully increase risk after adjustment.
Why this matters
This study highlights a core limitation of single-marker thinking:
ASCVD risk is multidimensional
Inflammation, thrombosis, and atherogenesis interact
“Average” risk estimates can obscure high-risk biological phenotypes
Notably, homocysteine—not currently a guideline risk enhancer—emerged as a powerful amplifier of risk when combined with inflammation and Lp(a).
Important nuance
Adding these biomarkers only modestly improved population-level prediction metrics (C-statistics). But for individual risk stratification, the signal is clinically meaningful.
Take-home message
ASCVD risk is not additive—it’s synergistic.
Looking at biomarker combinations, rather than single values, may better identify who truly carries residual cardiovascular risk.
Precision prevention beats one-number medicine.”
Read the full article here.
Article: Lipoprotein(a), high-sensitivity c-reactive protein, homocysteine and cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis
Authors: Sarah O. Nomura, Harpreet S. Bhatia, Parveen K. Garg, Amy B. Karger, Weihua Guan, Jing Cao, Michael D. Shapiro, Michael Y. Tsai
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 13, 2026, 21:01Leonardo Roever: Brain Age as a Biomarker of Neuroplasticity and Motor Recovery After Stroke
-
Mar 13, 2026, 20:50William Tembo: Understanding Stroke Through Landmark Clinical Trials
-
Mar 13, 2026, 20:35Jessica Garcia: New Evidence on Thrombin Generation Patterns in Children with Hemophilia A
-
Mar 13, 2026, 20:11Christoph B. Olivier: New Research from Marius Wessinger on Predicting Therapy Success After Pulmonary Embolism
-
Mar 13, 2026, 19:53Wolfgang Miesbach Announces the New English Edition of “Gene Therapy Concepts in the Treatment of Haemophilia”
-
Mar 13, 2026, 17:21Emmanuel J Favaloro: Acquired Hemostasis Disorders Featured in New Issue of Seminars in Thrombosis and Hemostasis
-
Mar 13, 2026, 17:17Paolo Zamboni: New Insights from Australia on Jugular and Azygous Vein Chronic Obstruction
-
Mar 13, 2026, 17:06Srishti Goyal: Can Thalassemia Major Be Prevented?
-
Mar 13, 2026, 16:59Tagreed Alkaltham: Preventing the Risk of Transfusion Reactions Before They Occur